Articles tagged with: Revlimid
Headline, News »
Combination therapy of Revlimid (lenalidomide) and Vidaza (azacitidine) was effective and well tolerated in high-risk myelodysplastic syndromes (MDS) patients, according to a Phase 1 study performed by United States researchers.
Vidaza is approved in the U.S. for all types of MDS patients, generally delays progression of MDS to acute myeloid leukemia, and improves overall survival. Revlimid is typically used to treat certain low- or intermediate-1 risk MDS patients.
The Phase 1 study results represented attempts by researchers to determine the maximum tolerated dose and the tolerability of the combination treatment…
News »
Telik Announces Phase 1 Study Of Telintra And Revlimid Combination Therapy for Myelodysplastic Syndromes Patients — Telik, Inc. announced the start of a Phase 1 clinical trial to test the safety, tolerability, and maximum tolerable dose of Telintra (ezatiostat hydrochloride) in combination with Revlimid (lenalidomide) for myelodysplastic syndromes (MDS) patients. Thirty low to intermediate-1 risk MDS patients will receive Telintra in increasing doses. The drug has recently shown positive results for MDS patients as a single agent, either orally or by intravenous injection, and continues to be evaluated as a single agent in a separate Phase 2 study. For more information, please see the Telik press release.
Company Developing Sapacitabine For Treatment Of Myelodysplastic Syndromes To Raise Millions In Direct Offerings — Cyclacel Pharmaceuticals, Inc. announced plans on January 21 to raise up to $7.9 million in capital through registered direct offerings to its investors. The company is currently testing sapacitabine for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and several other cancers. Interim results of an ongoing Phase 2 clinical trial in MDS were presented at the recent American Society of Hematology annual meeting (see related Beacon news). For more information, please see the Cyclacel press release.
Understanding Clinical Trials For Blood Cancers Like Myelodysplastic Syndromes, LLS Web Seminar — The Leukemia and Lymphoma Society (LLS) is sponsoring an online seminar (webinar) titled “Understanding Clinical Trials For Blood Cancers” on Thursday, January 28, from 7 p.m. to 8 p.m. EST. Dr. Karen Yee will explain clinical trials in detail, including how they are organized, safety concerns, and how myelodysplastic syndromes patients can participate. Registration is required. For more information, please visit the LLS Web site.
For a more detailed listing of MDS-related events, please check the MDS Beacon Events Calendar.
Headline, News »
Revlimid (lenalidomide) given at a dose of 10 mg may be the most effective initial dose for the treatment of myelodysplastic syndromes (MDS), according to the results of a Phase 3 study conducted by a team of international researchers. The findings were presented at the 51st Annual American Society of Hematology (ASH) meeting and exposition on December 8.
For MDS, Revlimid is typically used as a treatment for low- or intermediate-1 risk patients, especially those who require red blood cell transfusions and have del-5q. A del-5q mutation is a chromosomal…
Headline, News »
European researchers have found during a Phase 2 study that Revlimid (lenalidomide) produces an improved chromosomal response in High-risk myelodysplastic syndromes (MDS) patients. The results were presented today at the 51st annual American Society of Hematology (ASH) meeting.
Revlimid has already been used with Low- or Intermediate-1 risk MDS subtypes, especially those who require red blood cell transfusions or have del-5q, as it produces a high rate of transfusion independence and improved chromosomal abnormalities.
Patients with del-5q are missing the ‘q’ arm of chromosome 5.
Although the exact mechanism of…
Headline, News »
A new report by Italian researchers suggests that Revlimid (lenalidomide), administered to myelodysplastic syndromes (MDS) patients on alternate days, may offer comparable efficacy to the standard daily dosing regimen, but with reduced side effects and treatment costs.
In MDS, Revlimid is typically used as a treatment for Low- or Intermediate-1 risk patients, especially those who require red blood cell transfusions and have del-5q. A del-5q mutation is a chromosomal abnormality characterized by a missing ‘q’ arm of chromosome 5.
Revlimid is intended to help MDS patients achieve red blood cell transfusion independence, and is…